Introduction {#s1}
============

Colorectal cancer (CRC) is one of the most common malignancies and is ranked as the third leading cause of cancer-related deaths in the USA [@pone.0093756-Siegel1]. The incidence of CRC in Asian countries is increasing rapidly and has been considered to be similar to that of the Western countries [@pone.0093756-Sung1], [@pone.0093756-Byeon1]. Generally, CRC is thought to be a malignancy affecting mostly on the elderly persons, with more than 90% of patients being diagnosed after age 55 years [@pone.0093756-Atkin1]. The 2010 Annual Report to the Nation on Cancer celebrated a steady decline in the incidence of CRC in USA [@pone.0093756-Edwards1]. In sharp contrast to overall trends, the incidence of CRC in young patients appears to be increasing [@pone.0093756-Edwards1], [@pone.0093756-OConnell1], [@pone.0093756-OConnell2]. The incidence of the disease, considering patients aged between 20--40 years of age increased by 17% during the period between 1973 and 1999 [@pone.0093756-OConnell2].

CRC in the young generally regards as a higher prevalence of mucinous or poorly differentiated tumors including signet ring carcinoma and later stage, which tend to have a poorer prognosis compared to elderly patients [@pone.0093756-Varma1], [@pone.0093756-Nakamura1], [@pone.0093756-Heimann1], [@pone.0093756-Chan1]. Some authors, however, argued that compared with the elderly patients, although the young ones have unfavorable cliniopathological characteristics, they have better, at least no worse, long-term survival rates than elderly [@pone.0093756-Li1], [@pone.0093756-Schellerer1], [@pone.0093756-Kam1]. Most of the published studies on CRC in young patients are single-institution experiences or limit sample sizes. In this regard, we used data from the Surveillance, Epidemiology and End Results (SEER) registries to analysis age role on CRC long time survival after surgery.

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

The current SEER database consists of 17 population-based cancer registries that represent approximately 26% of the population in the United States. The SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and health policy. The National Cancer Institute's SEER\*Stat software (Surveillance Research Program, National Cancer Institute SEER\*Stat software, [www.seer.cancer.gov/seerstat](http://www.seer.cancer.gov/seerstat))(Version 8.1.2) was used to identify patients whose pathological diagnosis as invasive CRC (C18.0--20.9) between 1988, and 2003. Only patients who underwent surgical treatment with age of diagnosis between 18 and 74 years were included. Patients were excluded if they had in situ or incomplete TNM staging, with distant metastasis (M1), no evaluation on lymph nodes (LNs) or differentiation grade or histological type pathologically, died within 30 days after surgery, or multiple primary malignant neoplasm as determined by Extent of Disease Codes. Age, sex, race, TNM stage, tumor grade, tumor location, CRC--specific survival (CCSS) was assessed. The lymph nodes ratio (LNR) was calculated as the number of positive regional nodes divided by the number of regional nodes examined and defined as the rN classification. Adjuvant chemotherapy was not evaluated as the SEER registry does not include this information. TNM classification was restaged according to the criteria described in the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (7th edition, 2010). The primary endpoint of study is CCSS which was calculated from the date of diagnosis to the date of cancer specific death. Deaths attributed to the cancer of interest are treated as events and deaths from other causes are treated as censored observation.

This study was based on public data from the SEER database and we had got the permission to access the research data files with the reference number 12768-Nov2012. It didn't include interaction with human subjects or use personal identifying information. The study did not require informed consent and was approved by the Review Board of Fudan University Shanghai Cancer Center, Shanghai, China.

Statistical Analysis {#s2b}
--------------------

Association of age (young and elderly) with clinicopathological parameters was analyzed by chi-square (χ2) test. Continuous variables were analyzed using Student's t-test. Survival curves were generated using Kaplan-Meier estimates, differences between the curves were analyzed by log-rank test. Multivariable Cox regression models were built for analysis of risk factors for survival outcomes. All statistical analyses were performed using the statistical software package SPSS for Windows, version 17 (Chicago: SPSS Inc, USA). Results were considered statistically significant when a two-tailed test of P\<0.05 achieved.

Results {#s3}
=======

Patient Characteristics {#s3a}
-----------------------

We identified 69,835 eligible patients with CRC in SEER database during the 15-year study period (between 1988 and 2003). There were 37,130 (53.17%) males and 32,705(46.83%) females. The median ages in young and elderly groups were 36(15--40) and 64(41--74), respectively. The median follow-up period was 97(1--275) months. Patient demographics and pathological features are summarized in [Table 1](#pone-0093756-t001){ref-type="table"}.

Clinicopathological Differences between the Two Groups {#s3b}
------------------------------------------------------

When compared to elderly patients, in group of young ones, it was investigated that significant differences were found among the years of diagnosis (more frequent in recent years(2000--2003), P\<0.001), race (less frequent in Caucasian race, p\<0.001), pathological grading (more poor or undifferentiation in grade, p\<0.001), histological type (more mucinous or signet-ring cancer, p\<0.001), AJCC stage (more stage III, p\<0.001), No. of LNs dissected (more cases with ≥12 LNs dissected, p\<0.001) and LNR(more rN1, p\<0.001). As regard to sex (p = 0.62) and primary site (p = 0.43), no significant differences between two groups were found. ([Table 1](#pone-0093756-t001){ref-type="table"}).

10.1371/journal.pone.0093756.t001

###### Characteristics of Patients from SEER Database by age.

![](pone.0093756.t001){#pone-0093756-t001-1}

                            Total   Young Group   Elderly Group   P value
  ------------------------ ------- ------------- --------------- ----------
  Media foullow up(mo)                  112            98         P\<0.001
  (IQR)                               58--158        42--135     
  Years of diagnosis                                              P\<0.001
  1988--1993                16017       609           15408      
  1994--1999                21295       955           20340      
  2000--2003                32523      1450           31073      
  Sex                                                              0.615
  male                      37130      1589           35541      
  female                    32705      1425           31280      
  Race                                                            P\<0.001
  Caucasian                 55824      2183           53641      
  African American          7390        431           6954       
  Others                    6443        391           6052       
  Unknowns                   178         9             169       
  Primary site                                                     0.434
  Colon cancer              51372      2236           49136      
  Rectal cancer             18463       778           17685      
  Pathological grading                                            P\<0.001
  High/Moderate             54812      2167           52645      
  Poor/undifferentiation    12644       723           11921      
  Histological Type                                               P\<0.001
  Adenocarcinoma            61384      2455           58929      
  Mucinous cancer           7804        474           7330       
  Signet-ring cancer         647        85             562       
  AJCC stage                                                      P\<0.001
  I                         4563        133           4430       
  II                        35867      1384           34483      
  III                       29405      1497           27908      
  No. of LNs dissected                                            P\<0.001
  \<12                      37653      1037           36616      
  ≥12                       32182      1977           30205      
  Metastasis LNR                                                  P\<0.001
  rN0(0)                    40546      1521           39025      
  rN1(0.01--0.20)           12814       722           12092      
  rN2(0.21--0.60)           11482       541           10941      
  rN3(\>0.60)               4993        230           4763       

Impact of Age on CRC Survival Outcomes {#s3c}
--------------------------------------

The overall 5-year CCSS was 78.6% in young group and 75.3% in elderly group, which had significant difference in univariate log-rank test (P\<0.001) ([Fig. 1](#pone-0093756-g001){ref-type="fig"}). Besides, early year of diagnosis (P\<0.001), male (P\<0.001), African race (P\<0.001), rectal cancer (P\<0.001), poor or undifferentiation tumor grade (P\<0.001), mucinous or signet-ring cancer (P\<0.001), higher AJCC stage(P\<0.001), less number in LNs dissection(p\<0.01) and higher metastatic LNR(P\<0.001), were identified as significant risk factors for poor survival on univariate analysis([Table 2](#pone-0093756-t002){ref-type="table"}). When multivariate analysis with Cox regression was performed, we convinced all these factors as independent prognostic factors ([Table 3](#pone-0093756-t003){ref-type="table"}). These included age (elderly, hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.32--1.52), year of diagnosis (1994--1999, HR 0.83, 95% CI 0.80--0.86; 2000--2003, HR 0.74, 95% CI 0.71--0.76), gender (female, HR 0.87, 95%CI 0.85--0.90), race(African American, HR 1.19,95%CI 1.14--1.25;others, HR 1.59,95%CI 1.50--1.69), primary site(rectal cancer, HR 1.10,95%CI 1.07--1.14), pathological grading(poor or undifferentiation tumor, HR 1.32,95%CI 1.28--1.37), histological type(mucinous cancer, HR 1.10,95%CI 1.03--1.12; signet-ring cancer, HR 1.72,95%CI 1.54--1.92), AJCC stage(stage II, HR 2.91,95%CI 2.59--3.27; stage III, HR 4.83,95%CI 3.32--7.03), metastatic LNR(rN2, HR 1.92,95%CI 1.34--2.75; rN3, HR 3.23,95%CI 2.26--4.63), while the risk between rN0 and rN1 was not statistical difference(P = 0.45).

![Survival curves in CRC patients according to age status.\
Young group vs. Elderly group, *χ2 = 35.84, P\<0.001*.](pone.0093756.g001){#pone-0093756-g001}

10.1371/journal.pone.0093756.t002

###### Univariate survival analyses of CRC patients according to various clinicopathological variables.

![](pone.0093756.t002){#pone-0093756-t002-2}

  Variable                                     n     5-year CCSS (%)   Log rank χ^2^ test      P
  ----------------------------------------- ------- ----------------- -------------------- ----------
  Years of diagnosis                                                         333.65         P\<0.001
  1988--1993                                 16017        70.9%                            
  1994--1999                                 21295        74.6%                            
  2000--2003                                 32523        78.3%                            
  Sex                                                                        105.86         P\<0.001
  male                                       37130        74.4%                            
  female                                     32705        76.7%                            
  Age                                                                        35.84          P\<0.001
  ≤40                                        3014         78.6%                            
  41--74                                     66821        75.3%                            
  Race                                                                       195.16         P\<0.001
  Caucasian                                  55824        76.0%                            
  African American                           7390         69.3%                            
  Others[\*](#nt101){ref-type="table-fn"}    6621         78.1%                            
  Primary site                                                               144.24         P\<0.001
  Colon cancer                               51372        76.1%                            
  Rectal cancer                              18463        73.6%                            
  Pathological grading                                                      1128.17         P\<0.001
  High/Moderate                              54812        78.3%                            
  Poor/undifferentiation                     12644        63.5%                            
  Histological Type                                                          584.49         P\<0.001
  Adenocarcinoma                             61384        76.3%                            
  Mucinous cancer                            7804         71.7%                            
  Signet-ring cancer                          647         42.6%                            
  AJCC stage                                                                7353.52         P\<0.001
  I                                          4563         96.2%                            
  II                                         35867        85.4%                            
  III                                        29405        60.1%                            
  No. of LNs dissected                                                       36.93          P\<0.001
  \<12                                       37653        74.7%                            
  ≥12                                        32182        76.3%                            
  Metastasis LNR                                                            11590.57        P\<0.001
  rN0(0)                                     40546        86.6%                            
  rN1(0.01--0.20)                            12814        72.3%                            
  rN2(0.21--0.60)                            11482        56.3%                            
  rN3(\>0.60)                                4993         36.8%                            

\*including other (American Indian/AK Native, Asian/Pacific Islander) and unknowns.

10.1371/journal.pone.0093756.t003

###### Multivariate Cox model analyses of prognostic factors of CRC.
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  Variable                                   Hazard Ratio      95%CI          P
  ----------------------------------------- -------------- -------------- ----------
  Years of diagnosis                                                       P\<0.001
  1988--1993                                    1.000                     
  1994--1999                                    0.827       0.798--0.857  
  2000--2003                                    0.735       0.710--0.760  
  Sex                                                                      P\<0.001
  male                                          1.000                     
  female                                        0.874       0.850--0.899  
  Age                                                                      P\<0.001
  ≤40                                           1.000                     
  41--74                                        1.415       1.315--1.523  
  Race                                                                     P\<0.001
  Caucasian                                     1.000                     
  African American                              1.194       1.136--1.254  
  Others[\*](#nt102){ref-type="table-fn"}       1.593       1.498--1.693  
  Primary site                                                             P\<0.001
  Colon cancer                                  1.000                     
  Rectal cancer                                 1.104       1.071--1.138  
  Pathological grading                                                     P\<0.001
  High/Moderate                                 1.000                     
  Poor/undifferentiation                        1.322       1.279--1.366  
  Histological Type                                                        P\<0.001
  Adenocarcinoma                                1.000                     
  Mucinous cancer                               1.075       1.029--1.123  
  Signet-ring cancer                            1.716       1.537--1.917  
  AJCC stage                                                               P\<0.001
  I                                             1.000                     
  II                                            2.905       2.586--3.265  
  III                                           4.826       3.315--7.026  
  No. of LNs dissected                                                      0.063
  \<12                                          1.000                     
  ≥12                                           0.973       0.946--1.001  
  Metastasis LNR                                                           P\<0.001
  rN0(0)                                        1.000                     
  rN1(0.01--0.20)                               1.149       0.802--1.646  
  rN2(0.21--0.60)                               1.918       1.340--2.746  
  rN3(\>0.60)                                   3.233       2.257--4.633  

\*including other (American Indian/AK Native, Asian/Pacific Islander) and unknowns.

Stratified Analysis of Age on Cancer Survival Based on Different Stages {#s3d}
-----------------------------------------------------------------------

We then made further analysis of age on 5-year CCSS in each stage. The results showed that young patients were significantly associated with better 5-year CCSS than elderly patients in univariate analysis in both stage II and III(P\<0.001), but not in stage I (P = 0.605)([Table 4](#pone-0093756-t004){ref-type="table"}). And age was also validated as independent survival factor in multivariate Cox regression in stage II (elderly, HR 1.71, 95%CI 1.47--2.00, p\<0.001) and stage III (elderly, HR 1.33, 95%CI 1.22--1.45, p\<0.001) patients([Table 5](#pone-0093756-t005){ref-type="table"}).

10.1371/journal.pone.0093756.t004

###### Univariate analysis of Age on CCSS based on different stages.
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  Variable           n     5-year survival (%)   Log rank χ^2^ test      P
  --------------- ------- --------------------- -------------------- ----------
  **Stage I**                                                        
  Age                                                  0.575           0.448
  ≤40               133           96.9%                              
  41--74           4430           96.2%                              
  **Stage II**                                                       
  Age                                                  56.979         P\<0.001
  ≤40              1384           90.5%                              
  41--74           24483          85.2%                              
  **Stage III**                                                      
  Age                                                  29.677         P\<0.001
  ≤40              1497           65.9%                              
  41--74           27908          59.8%                              

10.1371/journal.pone.0093756.t005

###### Multivariate Cox model analyses of prognostic factors of CRC on different stages.
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  Variable         Hazard Ratio      95%CI          P
  --------------- -------------- -------------- ----------
  **Stage II**                                  
  Age                                            P\<0.001
  ≤40                 1.000                     
  41--74              1.709       1.465--1.995  
  **Stage III**                                 
  Age                                            P\<0.001
  ≤40                 1.000                     
  41--74              1.329       1.222--1.445  

P values refer to comparison between two groups and were adjusted for years of diagnosis, sex, age, race, primary site, pathological grading, tumor histotype, No. of LNs dissected, Metastasis LNR as covariates.

Discussion {#s4}
==========

The current definition of young CRC patients remains controversial. Some studies used the cutoff age of 50 years [@pone.0093756-Benmoussa1], , while others used 30 years [@pone.0093756-Kam1], [@pone.0093756-Neufeld1] or 45 years [@pone.0093756-Mitry1]. But to date, majority of studies in the literature used the cutoff age of 40 years to denote a young patients with CRC [@pone.0093756-OConnell1], [@pone.0093756-Li1], [@pone.0093756-Neufeld1], [@pone.0093756-Karsten1], [@pone.0093756-Taylor1]. This lack of a standard definition makes it difficult to make meaningful comparisons between different studies. We defined young patients using an upper limit of 40 years as most studies reported. In our study, the proportion of young patients with CRC with treatment of surgery has raised from 3.80%(609/15408) in year of 1988--1993 to 4.46%(1450/32523) in year of 1999--2003, which was consistent with the published epidemiologic feature [@pone.0093756-Edwards1], [@pone.0093756-Siegel2].

Various studies have reported poorer prognosis among young patients with CRC. Taylor et al. [@pone.0093756-Taylor1] in their review demonstrated that when compared to elderly patients, young patients less than 40 years of age presented with more advanced lesions and had lower survival rates. Similar results were reported by Marble et al [@pone.0093756-Marble1] and Cusack et al [@pone.0093756-Cusack1]. This reduction in survival has been attributed to more advanced disease at diagnosis [@pone.0093756-OConnell1], [@pone.0093756-BenIshay1], [@pone.0093756-Karsten1]. Tumor stage was very powerful factor effect long time survival rate. Poor tumor differentiation and mucinous and signet-ring cancer were also characteristic histological features in these patients [@pone.0093756-OConnell1]. It is well known that mucinous, signet-ring and poorly differentiated tumors tend to have a poorer prognosis compared to well and moderately differentiated tumors [@pone.0093756-Adkins1], Our study show that 5-year CCSS of adenocarcinoma, mucinous and signet-ring cancer was 76.3%, 71.7% and 42.6% respectively, signet-ring cancer is at extremely low rate.

In this cohort, despite the significantly higher incidence of poor prognostic factors such as poorly differentiated tumors, mucinous and signet-ring cancer, advanced AJCC stage in young group compared with the patients over 40 years of age, young CRC patients had a better 5-year CCSS, especially in stage II and stage III. This is demonstrated on both univariate and multivariate analysis. Our result is consist with some recently published articles [@pone.0093756-Li1], [@pone.0093756-Schellerer1]. In this study, we included 3,014 young CRC patients, which is to date the largest number, and excluded CRC patients over 75 years old for short life expectation, which made our results more convincing. Young patients have a poorer biological behavior of carcinoma, but this is compensated by the better overall condition, faster postoperative recovery. In general, a good performance status is essential for the success of chemotherapy [@pone.0093756-Goodwin1] and extensive lymphadenectomy. Clinicians are more inclined to gain all therapeutical options in young patients as they are at a better health condition and are more likely to tolerate toxicities associated with chemotherapy [@pone.0093756-Chew1] while elderly patients always undertreated because of their age [@pone.0093756-SerraRexach1]. Adjuvant chemotherapy isn't indication for stage I patients, which could help explaining why there weren't significant difference in CCSS between young and elderly patients in this stage. Young patients also have a higher proportion of tumors demonstrating microsatellite instability, which are associated with a better prognosis [@pone.0093756-Popat1]. Examination of at least 12 lymph nodes in the staging of CRC was recommended by the National Comprehensive Cancer Network (NCCN) and American Society for Clinical Oncology (ASCO) and about 65.59%(1977/3014) young CRC patients met this criterion compared with 45.20%(30205/66821) in elderly patients, which difference is statistical. Evaluation of an increasing number of lymph nodes has been shown to be associated with improved survival after resection of colon cancer [@pone.0093756-Chang1], [@pone.0093756-LeVoyer1], but the level of significance just failed in multivariable Cox regression models in our study (P = 0.063). we also verified metastatic LNR as an independent prognosis factors by rN classification used by Zhang et al [@pone.0093756-Zhang1].

Although this is a large population-based study evaluating prognosis of young patients with CRC, it has several potential limitations. First, the SEER database lacks several important tumor characteristics (eg, perineural invasion and lymphovascular invasion), cancer therapy (neoadjuvant and adjuvant, quality of surgery). Thus, our analyses could not adjust for these potential confounding factors. Second, this data include only patients who had undergone surgical resection for CRC. As such, this group of patients can not represent CRC patients who had irresectable tumors or refused surgical intervention for various reasons. Still, our study has its convincing power regarding young CRC good survival rate after surgery.

In summary, compared to elderly patients, young patients with CRC aged 40 and below appear to have unique characteristics and have a higher CCSS after surgery although they presented with higher proportions of unfavorable biological behavior as well as advanced stage disease.
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